Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) completed treatment for all 24 participants in Part A of its FDA‑regulated Phase I/II trial of CMND‑100 for Alcohol Use Disorder (AUD). The multicenter study spans four cohorts at leading sites in the United States and Israel.
Clearmind is reviewing the dataset and, if results remain favorable, plans to initiate the next stage of the AUD clinical program.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech, received U.S. patent No. 12,350,242 titled “BINGE BEHAVIOR REGULATORS” from the USPTO.
The patent covers MEAI-based compositions using pharmaceutically acceptable salts to regulate binge behaviors and lifts Clearmind’s global portfolio to 32 granted patents, supporting programs like CMND-100 for binge-related and CNS disorders.
Clearmind Medicine (Nasdaq: CMND) reported completion of dosing for all 24 participants in Cohorts 1–4 (Part A) of its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder. The multicenter, randomized, double-blind, placebo-controlled study uses escalating doses in healthy participants.
According to Clearmind, interim data from the first three cohorts continue to indicate a strong safety profile, supported by rapid enrollment and efficient execution at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center sites.
Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins,” on June 10, 2026, from 12:00–1:00 PM EDT.
The event will review early clinical data from the FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. Yale’s Dr. Anahita Bassir Nia and Johns Hopkins’ Dr. Jennifer Ellis will discuss findings, while CEO Dr. Adi Zuloff-Shani provides a clinical and corporate update. The webinar, moderated by Shannon Smadella, is free, open to the public, and requires Eventbrite registration.
Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio. MEAI is a non-hallucinogenic molecule intended as an alternative to SSRIs and psychedelic-based therapies.
The company highlights large and growing anxiety, depression, and broader behavioral health markets, including an estimated $16–22.65 billion global anxiety and depression market in 2025. Japan has about 3 million diagnosed MDD cases. Clearmind is also researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental health indications.
Clearmind Medicine (Nasdaq: CMND) received Johns Hopkins Medicine IRB approval to advance its ongoing Phase I/II CMND-100 trial. The multicenter study in healthy volunteers and Alcohol Use Disorder (AUD) subjects can now proceed to Parts B and C, following successful completion of earlier stages.
Clearmind Medicine (Nasdaq: CMND) approved a 1-for-10 reverse share split of its issued and outstanding common shares, effective May 21, 2026. The action is part of a plan to regain compliance with the Nasdaq Minimum Bid Price Rule.
Issued and outstanding shares will be adjusted from 10,190,337 to approximately 1,019,033, while authorized share capital remains unlimited. No fractional shares will be issued; fractions will be rounded up, and all outstanding options and warrants will be adjusted proportionately.
Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12‑month preclinical study of MEAI (CMND‑100) with tirzepatide in diet‑induced obese mice.
The study will assess combination and maintenance use in the fast‑growing $50–66B incretin therapeutics market.
Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani was named a delegate to the Psychedelic Medicine Coalition’s annual federal policy summit held May 14, 2026 at the National Press Club in Washington, D.C.
The summit gathered U.S. federal officials, legislators, researchers, clinicians and biopharma leaders to discuss psychedelic medicine policy. Clearmind is advancing a non-hallucinogenic psychedelic candidate in Phase IIa clinical trials at Johns Hopkins, Yale, and other leading sites.
Clearmind Medicine (Nasdaq: CMND) reported an important milestone in its FDA-approved Phase I/IIa trial of CMND-100 (MEAI) for moderate to severe alcohol use disorder, with 20 participants now treated across all cohorts.
The fourth cohort uses a 160 mg dose, initiated after a positive DSMB recommendation and successful completion of three cohorts (18 participants) that met the primary safety endpoint with no serious adverse events. The multinational, multicenter study assesses safety, tolerability, pharmacokinetics, and preliminary efficacy at leading institutions including Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center.